Molecular-targeted therapy of head and neck squamous cell carcinoma: Beyond cetuximab-based therapy

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 241-248

  MacHiels, Jean Pascal ^a   Schmitz, Sandra ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

epidermal growth factor receptor; squamous cell carcinoma; targeted agents; tyrosine kinase receptors

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PF 299804; PLACEBO; PLATINUM; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; ZALUTUMUMAB;

ALTERNATIVE MEDICINE; ANGIOGENESIS; ANTIBIOTIC PROPHYLAXIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PATHWAY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; LIVER FAILURE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SKIN ULCER; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR FISTULA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955012037     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328344f581     Document Type: Review

References (58)

1. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2-16. (Pubitemid 43199589)
2. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24:2666-2672. (Pubitemid 46622088)
3. Rubin Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGFa and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832. (Pubitemid 28280548)
4. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11:5856-5862. (Pubitemid 41170313)
5. Mrhalova M, PlzakJ, Betka J, Kodet R. Epidermal growth factor receptor: its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinoma. Neoplasm 2005; 52:338-343. (Pubitemid 41076203)
6. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176. (Pubitemid 46622295)
7. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome. J Clin Oncol 2007; 25:2164-2170.
8. Chiang WF, Liu SY, Yen CY, et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinoma. Oral Oncol 2008; 44:270-276.
9. Milas L, Mason K, Hunter N. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708. (Pubitemid 30111496)
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
12. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 2008; 11:1116-1127.
13. Rojo F, Gracias E, Villena N, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO foundation study. Clin Cancer Res 2010; 16:2474-2482.
14. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot phase II study for a new combined-modality paradigm. J Clin Oncol 2006; 24:1072-1078. (Pubitemid 46638804)
15. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2008; 26(Suppl):6006.
16. Kuhnt T, Sandner A, Wendt T, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21:2284-2289.
17. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010; 21:342-347.
18. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25:4880-4886. (Pubitemid 350220417)
19. Van Waes C, Allen CT, Citrin D, et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 77:447-454.
20. Vermorken JB, Remenar E, van Herpen C, et al., for the EORTC 24971/ TAX323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704.
21. Posner MR, HershockDM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. (Pubitemid 350005152)
22. Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:4448-4453.
23. Mesia R, Vazquez S, Grau JJ, et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN [abstract]. J Clin Oncol 2009; 27(Suppl):6015.
24. Kies MS, Holsinger FC, Lee JJ, William WN Jr, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28:8-14.
25. Wanebo H, Ghebremichael MS, Burtness B, et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303) [abstract]. J Clin Oncol 2010; 28(Suppl):5513.
26. Milas L, Fang FM, Mason KA, et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007; 67:568-572. (Pubitemid 46108328)
27. Cohen E, Haraf DJ, Kunnavakkam R, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010; 28:3336-3343.
28. Ferris RL, Heron DE, KimS, et al. Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): mature results with HPV analysis [abstract]. J Clin Oncol 2010; 28(Suppl):5515.
29. Mesia R, Rueda A, Vera R, et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial [abstract]. J Clin Oncol 2010; 28(Suppl):5534.
30. Vermorken J, Stohlmacher J, Davidenko I, et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB). Ann Oncol 2010; 21(S8):viii12.
31. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
32. BaselgaJ,TrigoJM, BourhisJ, et al. Phase II multicenter study of the epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of head and neck. J Clin Oncol 2005; 23:5568-5577.
33. Vermorken JB, Herbst RS, Leon X, et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112:2710-2719. (Pubitemid 351969215)
34. Machiels JP, Subramian S, Ruzsa A, et al. An open-label, randomized phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy [abstract]. J Clin Oncol 2010; 28(Suppl):LBA5506.
35. Cohen E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2659-2665. (Pubitemid 46622087)
36. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-1871.
37. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG) [abstract]. J Clin Oncol 2009; 27(Suppl):6011.
38. Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19:2013-2023. (Pubitemid 47353811)
39. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2006; 24(Suppl): 5568.
40. Harrington KJ, Berrier A, Robinson M, et al. Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28(Suppl):5505.
41. Specenier PM, Lalami Y, Vermorken J, et al. EORTC 24051: unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed bychemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC) [abstract]. J Clin Oncol 2009; 27(Suppl):6017.
42. YapTA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28:3965-3972.
43. Seiwert TY, Fayette J, Del Campo J, et al. Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN) [abstract 1011 PD]. Ann Oncol 2010; 21(Suppl 8):viii316.
44. Torres MA, Raju U, Molkentine D, et al. AC 480, formerly BMS-599626, a pan HER inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs 2010 [Epub ahead of print].
45. LeTourneau C, Winquist E, HotteSJ, et al. Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/ or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28(Suppl):5531.
46. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773. (Pubitemid 47372619)
47. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0420. J Clin Oncol 2010;28:3330-3335.
48. Machiels JP, Henry S, ZanettaS, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28:21-28.
49. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10:247-257.
50. Jun H, Chang M, Ko Y, et al. Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck [abstract]. J Clin Oncol 2009; 27(Suppl):6036.
51. SchmitzS, Kaminsky-Forrett M, Henry S, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02 [abstract]. J Clin Oncol 2010; 28(Suppl):5500.
52. Knowles LM, Stabile LP, Egloff AM, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009; 15:3740-3750.
53. Seiwert T, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021-3031.
54. Woenckhaus J, Steger K, Werner E, et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002; 198:335-342. (Pubitemid 35277384)
55. Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:1441-1446.
56. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005; 114:242-248. (Pubitemid 40194293)
57. Garrido-Laguna I, Janku F, Tsimberidou A, et al. Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/ mTOR pathway in patients with advanced cancer [abstract]. J Clin Oncol 2010; 28(Suppl):e1301 8.
58. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors [abstract]. J Clin Oncol 2010; 28(Suppl):2583.